Biolex Presents at AASLD Meeting Significant Tolerability Advantages of Locteron(R), Its Next-Generation Interferon for Hepatitis C
Biolex will present positive results from its Phase 2b clinical trial of Locteron for hepatitis C, which demonstrate strong anti-viral response and tolerability advantages.... [more]
